Trial
NCT05081180
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Central Nervous System Tumors
Intervention
Avelumab
Why stopped
The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination treatment in the participants treated.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-29